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InvasionMicroRNAs (miRNAs) are a class of small non-coding RNAs that have been suggested to play an
essential role in tumorigenesis. In this study, we show that miR-152 is signiﬁcantly downregulated
in non-small cell lung cancer (NSCLC) tissues and cell lines. Restoration of miR-152 signiﬁcantly
reduces proliferation, colony formation, migration and invasion of NSCLC cells. In addition, ADAM
metallopeptidase domain 17 (ADAM17) is identiﬁed as a target of miR-152 in NSCLC cells, and
miR-152-induced suppression of cell proliferation, colony formation, migration and invasion is
partially mediated by silencing of ADAM17 expression. Furthermore, ADAM17 inversely correlates
with miR-152 in NSCLC tissues. Collectively, our ﬁndings indicate that miR-152 acts as tumor
suppressor in NSCLC partially via targeting ADAM17.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is one of the most life-threatening tumors, with
approximately two million new cases diagnosed worldwide annu-
ally, and Non-small-cell lung cancer (NSCLC) accounts for 80% of
primary lung cancer [1]. Despite the improvements in therapeutic
modalities, the 5-year survival rate of NSCLC patients is still around
15% [2]. Thus, it is necessary to explore novel agents for NSCLC
treatment.
MicroRNAs (miRNAs) are small non-coding RNAs which regu-
late a variety of cellular processes via binding to the 30-untrans-
lated region (30-UTR) of target mRNAs, resulting in the
degradation of the mRNAs or inhibition of mRNAs translation [3].
Accumulating evidence shows that miRNAs play critical roles in
the regulation of cancer initiation and progression [4,5]. MiRNAs
can function as oncogenes or tumor suppressors depending on
their speciﬁc target genes and different cancers [6–8]. Dysfunction
of miRNAs occurred in many cancers and aberrantly altered
expression of miRNAs was involved in tumorigenesis. A variety of
miRNAs have been found to dysregulated in NSCLC, and many miR-
NAs regulate NSCLC progression [9,10]. miR-152 functions as a
tumor suppressor in some cancers [11,12], and it was also down-
regulated in NSCLC [13], but the detailed role of miR-152 in NSCLC
is unclear.In this study, we found that miR-152 was signiﬁcantly down-
regulated in NSCLC tissues and cell lines, and overexpression of
miR-152 substantially suppressed proliferation and motility of
NSCLC cells. ADAM metallopeptidase domain 17 (ADAM17) was
identiﬁed as a target of miR-152 in NSCLC cells, and miR-152-
induced suppression of proliferation and motility of NSCLC cells
was partially mediated by silencing of ADAM17 expression. Fur-
thermore, ADAM17 was inversely correlated with miR-152 in
NSCLC tissues.
2. Materials and methods
2.1. NSCLC cancer tissue and cell culture
Paired NSCLC and adjacent non-tumor normal lung tissues were
obtained from 30 patients with informed consent at our hospital.
Tissues were immediately snapfrozen and stored at 80 C. Four
NSCLC cell lines (A549, SK-MES-1, H157, and H520) and a normal
lung bronchus epithelial cell line BEAS-2B were obtained from
American Type Culture Collection and cultured in DMEM supple-
mented with 10% FBS (Invitrogen, Carlsbad, CA, USA), and incu-
bated in 5% CO2 humid atmosphere at 37 C.
2.2. Plasmid
miR-152 mimic/inhibitor was obtained from RiboBio (Guangz-
hou, China). pcDNA3-ADAM17 was generated by using primers:
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TTGCGGCCGCAAAGGAGAAGGGCCAAAC-30. 30-UTR of ADAM17
was ampliﬁed and cloned into the pGL-3-vector (Promega, Madison,
WI, USA). Mutations in the 30-UTR of ADAM17 with miR-152 target
site (Mut) was generated with a fast mutation kit (NEB, Ipswich,
Canada).
2.3. RNA isolation and quantitative real-time polymerase chain
reaction (qRT-PCR)
Total RNA was isolated with Trizol (Invitrogen, Carlsbad, CA,
USA). MicroRNA was isolated with the mirVana miRNA Isolation
Kit (Ambion, Austin, TX, USA). Expression of miR-152 was detected
using TaqMan MicroRNA Assay primers (ABI, Foster City, CA, USA).
U6 or GAPDH was used as an internal control. Experiments were
performed on the ABI Prism 7500 HT (ABI, Foster City, CA, USA).
The relative expression level was calculated by normalization with
the signal for U6 expression using 2DDCt method.
2.4. Cell proliferation assay
Transfected cells were seeded into 96-well plates with a density
of 4000 cells/well, and cultured for different time. 10 lL of MTT
was added into each well, and incubated for 4 h. Then the superna-
tant was discarded, and 200 lL of DMSO was added to each well.
Optical density (OD) was detected at the wavelength of 490 nm.
Data were derived from three independent experiments.
2.5. Colony formation assay
2000 transfected cells were seeded into 12-well plate. Approx-
imately 10 days later, the clones were washed with PBS and
stained with 0.5% crystal violet for 15 min. Finally the clones were
taken pictures and counted under a microscope (Olympus, Tokyo,
Japan).
2.6. Migration and invasion assays
Migration and invasion were examined using a transwell cham-
ber (Millipore, Billerica, MA, USA). For the migration assay, 1  105
transfected cells were plated into the upper chamber, and cultured
in DMEM, while DMEM with 10% FBS was added to the lower
chamber. After 24 h incubation at 37 C, cells remaining on the
upper surface of membrane was removed, and membrane was
stained with 20% methanol and 0.5% crystal violet. Cell images
were obtained using an inverted microscope (Olympus, Tokyo,
Japan). For invasion assays, the upper chamber was precoated with
Matrigel (BD, San Jose, CA, USA).Fig. 1. miR-152 was downregulated in NSCLC tissues and cell lines. (A) miR-152 was sig
tumor normal tissues. (B) miR-152 was signiﬁcantly decreased in four NSCLC cell lines
compared with the control group.2.7. Western blotting
Cultured cells were lysed in RIPA buffer with 1% PMSF. Protein
was loaded and seperated by SDS–PAGE gel and transferred onto
PVDF membrane. The blots were probed with primary antibodies
at 4 C overnight and subsequently incubated with HRP-
conjugated secondary antibodies. Signals were visualized using
ECL Substrates (Pierce, Rockford, IL, USA). GAPDH was used as an
endogenous control.
2.8. Luciferase assays
About 1  105 HEK293 cells per well were cultured in 24-well
plates. Cells were co-transfected with 10 ng pRL-TK Renilla lucifer-
ase reporter, 50 ng pGL-3 ﬁreﬂy luciferase reporter, and 100 nM
miR-152 mimics or control mimics using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA). Cell lysates were prepared 48 h
after transfection using Passive Lysis Buffer, and luciferase activity
was examined using the Dual-Luciferase Reporter Assay (Promega,
Madison, WI, USA). Results were normalized to the Renilla
luciferase.
2.9. Statistical analysis
Data are presented as mean ± SD. Statistical differences were
determined by ANOVA or Student t test. P < 0.05 was considered
signiﬁcant.
3. Results
3.1. miR-152 was downregulated in NSCLC tissues and cell lines
Expression of miR-152 in 30 paired NSCLC tissues was exam-
ined by qRT-PCR. We discovered that miR-152 was signiﬁcantly
downregulated in NSCLC tissues compared with the adjacent nor-
mal tissues (Fig. 1A). Furthermore, miR-152 was also downregu-
lated in four NSCLC cell lines compared with the normal lung
bronchus epithelial cell line BEAS-2B (Fig. 1B).
3.2. miR-152 suppressed NSCLC cell proliferation and colony formation
MTT and colony formation were used to determine the effects of
miR-152 on A549 and H520 cells. The expression of miR-152 mim-
ics was identiﬁed by qRT-PCR (Fig. 2A). Overexpression of miR-152
signiﬁcantly suppressed cell proliferation of A549 and H520 cells
compared with the scramble control (Fig. 2B). In consistent with
this result, miR-152 overexpression substantially suppressed
colony formation of A549 and H520 cells (Fig. 2C).niﬁcantly downregulated in NSCLC tissues compared with the corresponding non-
compared with the lung bronchus epithelial cell line BEAS-2B. ⁄P < 0.05, ⁄⁄P < 0.01
Fig. 2. miR-152 suppressed NSCLC cell proliferation and colony formation. (A) Expression of miR-152 in A549 or H520 cells transfected with miR-152 or the scramble control.
(B) MTT assay of A549 or H520 cells transfected with miR-152 or the scramble control. (C) Colony formation of A549 or H520 cells transfected with miR-152 or the scramble
control. Data were drawn from three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with the control group.
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We further investigated whether miR-152 could also inhibit
migration and invasion of NSCLC cells. Overexpression of miR-
152 dramatically suppressed tumor cell migration in A549 cells
compared with the scramble control (Fig. 3A). Similarly, transwell
assays with Matrigel demonstrated that miR-152 markedly
decreased the invasive capacity of A549 cells (Fig. 3B).
3.4. ADAM17 was a target of miR-152 in NSCLC cells
To identify the target of miR-152 in NSCLC, TargetScan 6.2 was
used. ADAM17, which was increased in NSCLC, was predicted to be
a potential target of miR-152 (Fig. 4A). Luciferase activity assay
found thatmiR-152 signiﬁcantly inhibited theWTbut notMut lucif-
erase activity in HEK293 cells (Fig. 4B). Moreover, overexpression of
miR-152 signiﬁcantly inhibited ADAM17 expression (Fig. 4C).3.5. miR-152 suppressed NSCLC progression partially by targeting
ADAM17
We further investigated that whether miR-152 suppressed
NSCLC progression by targeting ADAM17. MTT assay, colony for-
mation, migration and invasion (Fig. 5A–D) showed that supple-
ment of ADAM17 by pcDNA3-ADAM17 signiﬁcantly attenuated
the tumor suppressive effects of miR-152. The effect of ADAM17
plasmid was conﬁrmed by Western blotting (Fig. 5E).
3.6. miR-152 was inversely correlated with ADAM17 expression in
NSCLC tissues
Expression of ADAM17 in 30 NSCLC tissues was examined by
qRT-PCR. ADAM17 mRNA was remarkably increased in NSCLC tis-
sues (Fig. 6A). Furthermore, ADAM17 mRNA level was inversely
correlated with miR-152 level in NSCLC tissues (Fig. 6B).
Fig. 3. miR-152 suppressed NSCLC cell migration and invasion. (A) Migration assay of A549 cells transfected with miR-152 or the scramble control. (B) Invasion assay of A549
cells transfected with miR-152 or the scramble control. Data were drawn from three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with the control group.
Fig. 4. ADAM17 was a target of miR-152 in NSCLC cells. (A) The potential miR-152 binding sites of ADAM17 30-UTR and the mutant. (B) HEK293 cells were co-transfected
with miR-152 or the scramble control with WT or Mut ADAM17 30-UTR. Luciferase activity was assayed. (C) Protein level of ADAM17 was detected by Western blotting in
A549 cells transfected with miR-152 or the scramble control. GAPDH was used as an internal control. Experiments were performed in triplicate. ⁄⁄P < 0.01 compared with the
control group.
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In this study, we provide important evidence in support of miR-
152 functioning as a tumor suppressor in NSCLC. In addition, we
identiﬁed ADAM17 as a direct target of miR-152 in NSCLC cells.
Restoring the expression of ADAM17 could abolish miR-152-
mediated suppression of NSCLC progression. Moreover, ADAM17
was inversely correlated with miR-152 in NSCLC tissues.
miR-152 is a member of the miR-148/152 family which
includes miR-148a/b and miR-152. miR-152 was an tumor sup-
pressive miRNA and decreased in various types of cancer. Aberrant
expression of miR-152 was thought to contribute to the malignant
phenotype of several tumors. Huang et al. showed that miR-152
was decreased in hepatitis B virus-related hepatocellular carci-
noma (HCC), and forced expression of miR-152 in liver cells sup-
pressed the expression of DNA methyltransferase 1 (DNMT1),
leading to decrease in global DNA methylation [14]. These data
were consistent with the study of pancreatic cancer cells by Azizi
et al. [15]. Zhu et al. reported that miR-152 expression was
decreased in primary prostate cancer (PC), and low miR-152
expression is correlated with advanced pathological T-stages. They
further identiﬁed that TGFa, which was increased in PC, was a tar-
get of miR-152 [16]. Zheng et al. found that miR-152 and miR-15bsuppressed glioma cell invasion and angiogenesis by targeting
NRP-2 and MMP-3 [11]. Our data expanded the tumor suppressive
role of miR-152 in NSCLC. Forced expression of miR-152
suppressed A549 cells proliferation, colony formation, migration
and invasion.
ADAM17 is one kind of the superfamily of Zn-dependent
metalloproteinases, and regulates the cleavage of ectodomain of
several transmembrane proteins [17]. ADAM17 sheds many essen-
tial cell surface molecules, including cytokines and adhesion mol-
ecules [18]. Accumulating evidence suggests that ADAM17 was
increased in a variety of tumors, including gastric cancer, HCC,
colon cancer, breast cancer, and NSCLC [18–21]. The elevated
ADAM17 was involved in proliferation, chemoresistance, and
malignant phenotypes. Thus, ADAM17 has been considered as a
potential therapeutic target in several tumors [22]. Zheng et al.
showed that suppression of ADAM17 abolished hypoxia-mediated
brain tumor cell invasiveness [23]. Lv et al. found that downregu-
lation of ADAM17 expression suppressed the migration and inva-
sion of NSCLC cells [21]. In the present study, we identiﬁed that
ADAM17 was a target of miR-152 in NSCLC cells, and supplement
of ADAM17 remarkably attenuated the tumor suppressive effects
of miR-152 on NSCLC cells. In addition, ADAM17 was inversely
correlated with miR-152 in NSCLC tissues.
Fig. 5. miR-152 suppressed NSCLC progression partially by targeting ADAM17. (A) A549 cells were transfected with miR-152 with/without ADAM17 overexpression plasmid,
and MTT assay was performed. (B) Colony formation assay. (C) Migration assay. (D) Invasion assay. (E) Protein level of ADAM17. Experiments were performed in triplicate.
⁄P < 0.05, ⁄⁄P < 0.01 compared with control; #P < 0.05, compared with miR-152 transfected group.
Fig. 6. miR-152 was negatively correlated with ADAM17 in NSCLC tissues. (A) The expression of ADAM17 in 30 pairs of NSCLC tissues was measured by qRT-PCR. (B) ADAM17
mRNA level was inversely correlated with miR-152 level in NSCLC tissues (Spearman’s correlation analysis, r = 0.377, P = 0.04). ⁄P < 0.05 compared with control.
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152 acts as a tumor suppressor in NSCLC cells, which are largely
mediated through inhibiting of ADAM17 expression. These ﬁnd-
ings provide novel insight into the mechanisms of NSCLC.Conﬂict of interest
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